Y-Biologics, Inc. (KOSDAQ:338840)
South Korea · Delayed Price · Currency is KRW 24,900
+250 (1.01%)
At close: Apr 9, 2026
Y-Biologics Revenue
In the year 2025, Y-Biologics had annual revenue of 2.91B KRW, down -49.45%. Y-Biologics had revenue of 448.64M in the quarter ending December 31, 2025, a decrease of -60.90%.
Revenue
2.91B
Revenue Growth
-49.45%
P/S Ratio
129.74
Revenue / Employee
n/a
Employees
n/a
Market Cap
377.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.91B | -2.85B | -49.45% |
| Dec 31, 2024 | 5.76B | 2.28B | 65.64% |
| Dec 31, 2023 | 3.48B | -671.48M | -16.18% |
| Dec 31, 2022 | 4.15B | -696.78M | -14.37% |
| Dec 31, 2021 | 4.85B | -1.88B | -27.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 100.17B |
| NIBEC | 32.72B |
| Genome & Company | 24.59B |
| S.Biomedics | 16.55B |
| Bio Solution | 15.20B |
| TiumBio | 12.29B |
| Kangstem Biotech | 3.57B |
| IntoCell | 2.30B |